The estimated Net Worth of Kenneth Peist is at least $149 ezer dollars as of 1 October 2015. Kenneth Peist owns over 10,000 units of Amicus Therapeutics Inc stock worth over $148,617 and over the last 14 years Kenneth sold FOLD stock worth over $0.
Kenneth has made over 6 trades of the Amicus Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Kenneth exercised 10,000 units of FOLD stock worth $131,400 on 1 October 2015.
The largest trade Kenneth's ever made was buying 28,208 units of Amicus Therapeutics Inc stock on 29 September 2014 worth over $171,787. On average, Kenneth trades about 4,030 units every 19 days since 2011. As of 1 October 2015 Kenneth still owns at least 13,187 units of Amicus Therapeutics Inc stock.
You can see the complete history of Kenneth Peist stock trades at the bottom of the page.
Kenneth's mailing address filed with the SEC is 6 CEDAR BROOK DRIVE, , CRANBURY, NJ, 08512.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris és Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: